Concepedia

Author

Cristina Oprean

Victor Babeș University of Medicine and Pharmacy TimișoaraORCID

Also Known As

Alina Simona Muntean, C. Oprean, Cristina Marinela Oprean, Cristina Oprean, Cristina-Marinela Oprean, Oprean, Cristina

43

Publications

1.2K

Citations

13

H-Index

19

Concepts

All Affiliations

Victor Babeș University of Medicine and Pharmacy TimișoaraDnipro State Medical UniversityInstitute of Oncology Prof. Dr. Ion ChiricutaCarol Davila University of Medicine and PharmacyWest University of Timişoara
CO

About

Cristina Oprean is an author at Victor Babeș University of Medicine and Pharmacy Timișoara specializing in oncology, radiation oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

615

2

Pharmacology

4

4

537

3

Pathology

3

3

338

4

Health Sciences

1

1

21

5

Obstetrics

1

1

11

Cristina Oprean

×

14

Publications

1.1K

Citations

12

H-Index

YearCitations

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Véronique Dièras, Hyo S. Han, Bella Kaufman,

The Lancet Oncology

2020

306

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Matti Aapro, H. S. Rugo, Giada Rizzi,

Annals of Oncology

2014

244

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone,

Journal of Thoracic Oncology

2021

187

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Jérôme Fayette, Lori J. Wirth, Cristina Oprean,

Frontiers in Oncology

2016

102

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Matti Aapro, Meinolf Karthaus, Lee S. Schwartzberg,

Supportive Care in Cancer

2016

47

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill,

European Journal of Cancer

2017

46

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

Véronique Dièras, Heather Han, Bella Kaufman,

Annals of Oncology

2019

32

Perception of disease, dyadic coping, and the quality of life of oncology patients in the active treatment phase and their life partners: an approach based on the actor-partner interdependence model

Adelina Mihaela Ştefǎnuţ, Mona Vintilă, Larisa Maria Bădău,

Frontiers in Psychology

2023

22

Randomized Phase Ii Study of Mehd7945A (Mehd) Vs Cetuximab (Cet) in >= 2Nd-Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck (Rmscchn) Progressive On/After Platinum-Based Chemotherapy (Ptct)

Jérôme Fayette, Lori J. Wirth, Cristina Oprean,

Annals of Oncology

2014

21

Well-Being, Depression, and Anxiety following Oncoplastic Breast Conserving Surgery versus Modified Radical Mastectomy Followed by Late Breast Reconstruction

Daciana Grujic, Cătălina Giurgi-Oncu, Cristina Oprean,

International Journal of Environmental Research and Public Health

2021

18

Page 1